Dr. Carlos (test)
Data regarding the impact of overall treatment time in prostate radiotherapy are limited, mixed, and largely predates the dose escalation era [Amdur 1990, Thames 1995, Dong 2018]. Furthermore, to our knowledge there has been no such analysis with proton therapy and high grade disease, for which treatment time may have a greater impact on outcome. Therefore, we wish to utilize the PCG data to investigate the correlation between overall treatment time and biochemical control, partitioning cohorts primarily by Gleason score. We plan to use receiver operator characteristic curve analysis to determine an a priori value for overall treatment time, if one exists. We will also employ case control/propensity score matching techniques for robust comparison.